A defucosylated anti-CD44 monoclonal antibody 5-mG(2a)-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma

CD44 is widely expressed on the surface of most tissues and all hematopoietic cells, and regulates many genes associated with cell adhesion, migration, proliferation, differentiation, and survival. CD44 has also been studied as a therapeutic target in several cancers. Previously, an anti-CD44 monoclonal antibody (mAb), C(44)Mab-5 (IgG(1), kappa) was established by immunizing mice with CD44-overexpressing Chinese hamster ovary (CHO)-K1 cells. C(44)Mab-5 recognized all CD44 isoforms, and showed high sensitivity for flow cytometry and immunohistochemical analysis in oral cancers. However, as the IgG(1) subclass of C(44)Mab-5 lacks antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), the antitumor activity of C(44)Mab-5 could not be determined. In the present study, we converted the mouse IgG(1) subclass antibody C(44)Mab-5 into an IgG(2a) subclass antibody, 5-mG(2a), and further produced a defucosylated version, 5-mG(2a)-f, using FUT8-deficient ExpiCHO-S (BINDS-09) cells. Defucosylation of 5-mG(2a)-f was confirmed using fucose-binding lectins, such as AAL and PhoSL. The dissociation constants (K(D)) for 5-mG(2a)-f against SAS and HSC-2 oral cancer cells were determined through flow cytometry to be 2.8×10(−10) M and 2.6×10(−9) M, respectively, indicating that 5-mG(2a)-f possesses extremely high binding affinity. Furthermore, immunohistochemical staining using 5-mG(2a)-f specifically stained the membranes of oral cancer cells. In vitro analysis demonstrated that 5-mG(2a)-f showed moderate ADCC and CDC activities against SAS and HSC-2 oral cancer cells. In vivo analysis revealed that 5-mG(2a)-f significantly reduced tumor development in SAS and HSC-2 ×enografts in comparison to control mouse IgG, even after injection seven days post-tumor inoculation. Collectively, these results suggest that treatment with 5-mG(2a)-f may represent a useful therapy for patients with CD44-expressing oral cancers.